These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 7521788

  • 1. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma.
    Tanosaki R, Okamoto S, Akatsuka N, Ishida A, Michikawa N, Masuda Y, Uchida H, Murata M, Kizaki M, Ikeda Y.
    Cancer; 1994 Oct 01; 74(7):1939-44. PubMed ID: 7521788
    [Abstract] [Full Text] [Related]

  • 2. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
    Itoh K, Ohtsu T, Fukuda H, Sasaki Y, Ogura M, Morishima Y, Chou T, Aikawa K, Uike N, Mizorogi F, Ohno T, Ikeda S, Sai T, Taniwaki M, Kawano F, Niimi M, Hotta T, Shimoyama M, Tobinai K, Members of the lymphoma study group of the Japan Clinical Oncology Group (JCOG).
    Ann Oncol; 2002 Sep 01; 13(9):1347-55. PubMed ID: 12196359
    [Abstract] [Full Text] [Related]

  • 3. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Wunderlich A, Kloess M, Reiser M, Rudolph C, Truemper L, Bittner S, Schmalenberg H, Schmits R, Pfreundschuh M, Loeffler M, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Ann Oncol; 2003 Jun 01; 14(6):881-93. PubMed ID: 12796026
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen.
    Sawada KI, Sato N, Kohno M, Hannda H, Yasukouchi T, Tanngo M, Hirayama A, Koike T.
    Leuk Lymphoma; 1995 Dec 01; 20(1-2):103-9. PubMed ID: 8750630
    [Abstract] [Full Text] [Related]

  • 5. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
    Gómez H, Mas L, Casanova L, Pen DL, Santillana S, Valdivia S, Otero J, Rodriguez W, Carracedo C, Vallejos C.
    J Clin Oncol; 1998 Jul 01; 16(7):2352-8. PubMed ID: 9667250
    [Abstract] [Full Text] [Related]

  • 6. Dose-escalation of CHOP in non-Hodgkin's lymphoma.
    Santoro A, Balzarotti M, Tondini C, Zanini M, Giardini R, Latteri F, Rampinelli I, Bufalino R.
    Ann Oncol; 1999 May 01; 10(5):519-25. PubMed ID: 10416000
    [Abstract] [Full Text] [Related]

  • 7. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
    Smith GM, Child JA, Cullen MH, Bailey NP, Woodruffe CM, Fletcher J, Earl H, Barnard D.
    Hematol Oncol; 1996 Dec 01; 14(4):193-201. PubMed ID: 9267465
    [Abstract] [Full Text] [Related]

  • 8. Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma.
    Itoh K, Ohtsu T, Wakita H, Igarashi T, Ishizawa K, Onozawa Y, Fujii H, Minami H, Sasaki Y.
    Ann Oncol; 2000 Oct 01; 11(10):1241-7. PubMed ID: 11106111
    [Abstract] [Full Text] [Related]

  • 9. A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma.
    Meyer RM, Gyger M, Langley R, Lespérance B, Caplan SN.
    Leuk Lymphoma; 1998 Aug 01; 30(5-6):591-600. PubMed ID: 9711921
    [Abstract] [Full Text] [Related]

  • 10. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
    Stoppa AM, Bouabdallah R, Chabannon C, Novakovitch G, Vey N, Camerlo J, Blaise D, Xerri L, Resbeut M, Di Stefano D, Bardou VJ, Gastaut JA, Maraninchi D.
    J Clin Oncol; 1997 May 01; 15(5):1722-9. PubMed ID: 9164178
    [Abstract] [Full Text] [Related]

  • 11. Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma. The lenograstim/Lymphoma Study Group.
    Itoh K, Ohtsu T, Sasaki Y, Ogura M, Morishima Y, Kasai M, Chou T, Yoshida K, Ohno T, Mizorogi F, Uike N, Sai T, Taniwaki M, Ikeda S, Tobinai K.
    Leuk Lymphoma; 2000 Aug 01; 38(5-6):521-32. PubMed ID: 10953973
    [Abstract] [Full Text] [Related]

  • 12. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D.
    Lancet; 2013 May 25; 381(9880):1817-26. PubMed ID: 23615461
    [Abstract] [Full Text] [Related]

  • 13. Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.
    Gregory SA, Case DC, Bosserman L, Litwak DL, Berry WR, Kalman LA, Belt RJ, Saven A.
    Clin Lymphoma; 2003 Sep 25; 4(2):93-8. PubMed ID: 14556680
    [Abstract] [Full Text] [Related]

  • 14. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
    Doorduijn JK, van der Holt B, van Imhoff GW, van der Hem KG, Kramer MH, van Oers MH, Ossenkoppele GJ, Schaafsma MR, Verdonck LF, Verhoef GE, Steijaert MM, Buijt I, Uyl-de Groot CA, van Agthoven M, Mulder AH, Sonneveld P.
    J Clin Oncol; 2003 Aug 15; 21(16):3041-50. PubMed ID: 12915593
    [Abstract] [Full Text] [Related]

  • 15. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.
    Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN.
    J Clin Oncol; 1995 Dec 15; 13(12):2916-23. PubMed ID: 8523055
    [Abstract] [Full Text] [Related]

  • 16. Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
    Takano H, Sawada K, Sato N, Natoya A, Tarumi T, Hirayama S, Koizumi K, Takahashi TA, Sekiguchi S, Koike T.
    Leuk Lymphoma; 1996 May 15; 21(5-6):473-8. PubMed ID: 9172813
    [Abstract] [Full Text] [Related]

  • 17. CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis.
    Jacobson JO, Grossbard M, Shulman LN, Neuberg D.
    Clin Lymphoma; 2000 Dec 15; 1(3):211-7; discussion 218. PubMed ID: 11707832
    [Abstract] [Full Text] [Related]

  • 18. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
    Bartlett NL, Petroni GR, Parker BA, Wagner ND, Gockerman JP, Omura GA, Canellos GP, Robert M, Johnson JL, Peterson BA.
    Cancer; 2001 Jul 15; 92(2):207-17. PubMed ID: 11466671
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors.
    Talbot SM, Westerman DA, Grigg AP, Toner GC, Wolf M, Bishop J, McKendrick J, Zalcberg J, Levi J, Fox RM, Green MD.
    Ann Oncol; 1999 Aug 15; 10(8):907-14. PubMed ID: 10509151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.